ImmuneRegen News

National Cancer Institute Initiates Studies on ImmuneRegen BioSciences' Vaccine Adjuvant Candidate

January 27, 2010

ImmuneRegen BioSciences® Reports Additional Positive Results From Study of Homspera® in Treating Highly Pathogenic Influenza

January 5, 2010

ImmuneRegen BioSciences® Summarizes Previous 9 Months of Advances as Homspera® Development Continues

December 24, 2009

ImmuneRegen BioSciences'® Reports Efficacy of a New Adjuvant of a Preventive Cancer Vaccine

December 21, 2009

ImmuneRegen BioSciences'® Drug Candidate Homspera Confirms Efficacy as Cancer Vaccine Adjuvant

December 14, 2009

ImmuneRegen BioSciences® Reports Positive Results of Homspera® in Treating Highly Pathogenic Influenza

Novemeber 10, 2009

ImmuneRegen BioSciences® to Further Homspera® Research in Study Funded by U.S. Government

October 22, 2009

ImmuneRegen BioSciences® Initiates Homspera® Studies Against Global Influenza Threat

October 12, 2009

ImmuneRegen BioSciences® Announces Strategic Partnership With Azopharma Product Development Group, Inc.

September 23, 2009

ImmuneRegen BioSciences® Announces Partnership with Bachem, Inc., for Manufacturing of Homspera®

September 22, 2009

ImmuneRegen BioSciences® Partners with University of Rochester in BARDA Funding Bid

September 9, 2009

ImmuneRegen BioSciences® Announces Collaboration with Archimedes Development Limited

August 26, 2009

ImmuneRegen BioSciences® Confirms Homspera's Therapeutic Anti-Influenza Effect on Pandemic H1N1 Influenza Virus after Oral Administration

July 29, 2009

ImmuneRegen BioSciences® Announces IND Submission for Homspera® for the Treatment of Idiopathic Pulmonary Fibrosis

May 28, 2009

ImmuneRegen BioSciences® Enters into a Sponsored Research Agreement with the University of Pittsburgh

May 14, 2009

ImmuneRegen® Licenses Intellectual Property from University of Pittsburgh to Further Develop Proprietary Compound

April 30, 2009

ImmuneRegen BioSciences® Adds Renowned Scientists to Advisory Board

April 14, 2009

ImmuneRegen® BioSciences Partners with University of Rochester Scientist to Explore Homspera® Activity Against Pulmonary Fibrosis

April 7, 2009

ImmuneRegen® BioSciences to Present Homspera® Findings at BIO 2009

March 26, 2009

WaferGen Biosystems, ImmuneRegen® BioSciences and University of Texas Southwestern Medical Center to Collaborate on Novel Wound Healing Research

March 24, 2009

ImmuneRegen® Appoints Wound Healing and Tissue Regeneration Expert Spencer A. Brown, Ph.D. to Advisory Board

December 1, 2008

ImmuneRegen® BioSciences to Present at Rodman & Renshaw 10th Annual Global Healthcare Conference

November 6, 2008

ImmuneRegen® Scientist to Present Viprovex® Pre-Clinical Study Findings at 2008 BARDA Industry Day

September 24, 2008

UNC Charlotte to Evaluate Potential Adjuvant Activity of ImmuneRegen's Viprovex® With Cancer Vaccine

September 23, 2008

ASU's Biodesign Institute and ImmuneRegen® Collaborate to Investigate Possible Enhancement of Vaccine Against Norwalk Viruses

August 18, 2008

ImmuneRegen® BioSciences Confirms Homspera® Advances Wound Healing in Topical Application

August 13, 2008

IR BioSciences Holdings, Inc. Closes New $5 Million Funding Round

August 11, 2008

ImmuneRegen® BioSciences Advances Toward IND Filing

July 17, 2008

ImmuneRegen® BioSciences Confirms Adult Stem Cell Activity of Homspera® in Human Bone Marrow

June 9, 2008

ImmuneRegen® Appoints Renowned Hematologist Ivan N. Rich, Ph.D. to Advisory Board

May 6, 2008

ImmuneRegen® BioSciences to Provide Adjuvant to DynPort Vaccine Company for Development of an Inactivated Vaccine against Venezuelan Equine Encephalitis Virus

April 30, 2008

ImmuneRegen® and BioCure Collaborate on Novel Wound-Healing Product

April 24, 2008

ImmuneRegen® Releases Results from UMDNJ Study Confirming Homspera's Adult Stem Cell Activity

April 16, 2008

ImmuneRegen® BioSciences Signs Material Transfer Agreement with University of Medicine and Dentistry of New Jersey

April 1, 2008

ImmuneRegen® BioSciences Releases Study Results Showing Homspera™ Stimulates Adult Stem Cell Activity

March 27, 2008

ImmuneRegen® BioSciences and DelSite Biotechnologies Collaborate On New Flu Treatment

March 24, 2008

ImmuneRegen® BioSciences Signs Lovelace Respiratory Research Institute as Development and Regulatory Partner

February 19, 2008

ImmuneRegen® BioSciences Announces Material Transfer Agreement with HemoGenix®

January 28, 2008

ImmuneRegen® BioSciences Signs Material Transfer Agreement with Celgene Cellular Therapeutics

January 23, 2008

IR BioSciences Announces $3 Million Financing Agreement

January 9, 2008